NEUROENDOCRINE NEOPLASM
Clinical trials for NEUROENDOCRINE NEOPLASM explained in plain language.
Never miss a new study
Get alerted when new NEUROENDOCRINE NEOPLASM trials appear
Sign up with your email to follow new studies for NEUROENDOCRINE NEOPLASM, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo therapy shows promise for rare gut tumors
Disease control OngoingThis early-phase trial is testing a new drug (peposertib) combined with a radioactive treatment (lutetium Lu 177 dotatate) for people with a type of neuroendocrine tumor in the digestive system. The goal is to find the safest and most effective dose. About 29 adults with well-dif…
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 16, 2026 12:49 UTC
-
New drug shows promise in slowing advanced neuroendocrine tumors
Disease control OngoingThis study tests whether the drug cabozantinib can slow the growth of advanced neuroendocrine tumors (including carcinoid tumors) compared to a placebo. About 298 adults whose cancer worsened after prior treatment will receive either cabozantinib or a placebo pill. The main goal …
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 12, 2026 12:08 UTC
-
Cancer drug showdown: which combo works best for rare gut tumors?
Disease control OngoingThis study compares two drug combinations for people with advanced neuroendocrine tumors (a type of slow-growing cancer). One group gets octreotide plus interferon, the other gets octreotide plus bevacizumab. The goal is to see which combination better delays cancer growth. About…
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 11, 2026 11:57 UTC
-
New combo therapy shows promise for Hard-to-Treat neuroendocrine liver tumors
Disease control OngoingThis study tests whether adding the immunotherapy drug pembrolizumab to either liver-directed treatments (like ablation or radiation) or peptide receptor radionuclide therapy (PRRT) can shrink or control well-differentiated neuroendocrine tumors that have spread to the liver and …
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE2 • Sponsor: Nicholas Fidelman, MD • Aim: Disease control
Last updated Jun 09, 2026 12:06 UTC
-
New drug combo shows promise for rare gut tumors
Disease control OngoingThis study tests whether two drugs, lenvatinib and everolimus, can shrink or slow the growth of advanced carcinoid tumors that cannot be removed by surgery. About 36 adults with this rare cancer will receive the combination. The goal is to see how well the drugs control the disea…
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 08, 2026 13:13 UTC
-
New PET tracer could reveal hidden cancers
Diagnosis OngoingThis early-phase study tests a new imaging tracer called 68Ga-FAPI-46 in 26 people with various cancers. The tracer targets cells around tumors, potentially making cancers show up better on PET/CT scans. Researchers will compare the scan results with tissue samples to see if this…
Matched conditions: NEUROENDOCRINE NEOPLASM
Phase: PHASE1 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Diagnosis
Last updated Jun 15, 2026 19:07 UTC